Omabit
AI platform for life sciences to analyze genomic, clinical, and scientific data for R&D decisions.
Website: https://omabit.com/
Cover Block
Publicly reported
| Field | Value |
|---|---|
| Name | Omabit |
| Tagline | AI platform for life sciences to analyze genomic, clinical, and scientific data for R&D decisions. [Business Wire, October 2026] |
| Headquarters | San Francisco, United States [Business Wire, October 2026] |
| Founded | 2025 [Business Wire, October 2026] |
| Stage | Seed [Business Wire, October 2026] |
| Business model | SaaS |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | North America |
| Growth profile | Venture Scale |
| Founding team | Co-Founders (3+), Elena Cassidy, Jesse Eaton, Jay Sarkar [Business Wire, October 2026] |
| Funding label | Seed |
| Total disclosed funding | ~$2,000,000 [Business Wire, October 2026] |
Links
Publicly reported
- Website: https://omabit.com
- Team: https://omabit.com/team/
- News: https://omabit.com/news/
Summary and Signal
PUBLIC Omabit is a San Francisco life-sciences software startup building an AI platform that helps R&D teams analyze internal genomic, clinical, and scientific data alongside published research, and it merits attention now because it closed a $2 million seed round in October 2026 at a very early stage of company formation [Business Wire, October 2026] [GenomeWeb, October 2026]. Founded in 2025, the company is positioning itself around post-experiment scientific interpretation and decision support for drug development, with an initial user focus on clinical-development, biomarker, and translational teams rather than on wet-lab automation or primary data generation [Business Wire, October 2026]. Its public product claims center on helping users compare treatment-response differences, interpret findings against published studies and comparison datasets, and use those outputs to inform future trials or regulatory discussions, which suggests the differentiation rests on workflow synthesis across fragmented scientific evidence rather than on a disclosed proprietary model layer [Business Wire, October 2026].
The founding team combines domain and machine-learning credentials, according to company and LinkedIn materials: CEO Elena Cassidy is described as having prior assay-development experience at Avida Biomed and Natera, CTO Jesse Eaton as having worked on large language models at Meta and machine learning at Freenome, and CSO Jay Sarkar as a Stanford-trained biophysicist and repeat biotech founder [Omabit] [LinkedIn] [Business Wire, October 2026]. Omabit also lists Stanford professor Michael Snyder as a scientific adviser, a credible signal for an early scientific software company, although the public record does not yet establish commercial traction, customer references, or production deployments [Business Wire, October 2026]. On capitalization, the only disclosed financing is the $2 million seed led by Bright Ventures, and the company says the proceeds will support platform development and expansion of scientific and engineering capacity; the business model is SaaS, but pricing, contract structure, and sales motion are not yet public [Business Wire, October 2026] [Datapile, October 2026].
Over the next 12 to 18 months, the public case will turn less on narrative and more on proof points: named customers, evidence that regulated life-science teams will adopt natural-language scientific analysis in live workflows, and signs that Omabit can convert scientific credibility into repeatable enterprise software demand [Business Wire, October 2026] [Omabit, June 2026]. Early ecosystem signals are constructive, including StartX participation in Summer 2026, but the company remains at a stage where most of the substantive product and team claims still trace back to company-controlled sources, so public investors should treat the opportunity as promising but still lightly verified [Omabit, June 2026] [Business Wire, October 2026].
No independent source found -- This section relies materially on company announcement, company website, and LinkedIn-sourced biographical claims, with independent corroboration for the seed round from GenomeWeb.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | SaaS |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | $2,000,000 seed disclosed |
Company Overview
PUBLIC
Omabit enters the record with a very short but clear public history. The company is based in San Francisco and was founded in 2025, according to its structured company profile and public company materials [Omabit, June 2026]. Public positioning describes Omabit as a life-sciences AI software company focused on helping drug-development and related scientific teams analyze genomic, clinical, and research data for R&D decision-making [Omabit, June 2026].
The milestone trail is limited but coherent. Omabit announced its acceptance into the StartX Summer 2026 cohort on June 7, 2026, which is the earliest dated company milestone surfaced in the public materials provided here [Omabit, June 2026]. The next verified step is the October 2026 seed financing announcement, when the company disclosed a $2 million seed round led by Bright Ventures to support continued platform development and growth of its scientific and engineering capacity [Business Wire, October 2026].
The founding team publicly listed around the company consists of Elena Cassidy, Jesse Eaton, and Jay Sarkar [Omabit]. No state filing or legal-entity detail was surfaced in the cited company materials for this section, so the overview stops at the operating profile the company has disclosed publicly [Omabit].
One source, partially checked -- Company overview is supported primarily by Omabit's website and company materials, with limited independent corroboration in the sources allowed for this section.
The Product and the Stack
MIXED
The product story is still narrow in the public record, but the core use case is legible. Omabit describes its platform as software for life-science R&D teams that combines a company’s internal genomic, clinical, and other scientific data with relevant published research, then uses analysis and predictive modeling to support research and development decisions [Business Wire, October 2026]. In plain terms, the company is positioning itself as a post-experiment interpretation layer rather than a lab automation tool, with initial users identified as clinical-development, biomarker, and translational teams [Business Wire, October 2026].
The functional claims are also concentrated around decision support after data has already been generated. According to the seed announcement, users can analyze treatment-response differences, compare findings against published studies and reference datasets, and use those outputs to plan future trials or support regulatory discussions [Business Wire, October 2026]. Omabit’s website summarizes that pitch more tersely, stating that it helps teams determine who responded, at what dose, and why [Omabit]. Those claims suggest a workflow aimed at translational interpretation and hypothesis formation, although the public material does not yet document a verified product demo, named deployment, or third-party validation of model performance [Business Wire, October 2026] [GenomeWeb, October 2026].
A few additional capability descriptions appear in company-controlled or adjacent channels, but they should be treated cautiously. A web-grounded research brief attributes to Omabit support for natural-language investigation of variants, biomarkers, gene essentiality, differential expression, and pathways, along with automatic generation of reports and figures without coding; because those details are not independently corroborated in the named-publisher coverage provided here, they remain company-level claims rather than confirmed product evidence [Business Wire, October 2026]. The practical takeaway is that Omabit appears to be aiming for an interface that reduces the need for bespoke bioinformatics work at the point of scientific interpretation, but the public evidence is still too early to establish depth, accuracy, or defensibility of the underlying system [GenomeWeb, October 2026] [Business Wire, October 2026].
No independent source found -- This section relies primarily on company-announced product claims in Business Wire and the company website, with limited independent corroboration from GenomeWeb on positioning but not on technical performance.
The Market They Are Entering
PUBLIC
This market matters now because biopharma teams are sitting on more molecular and clinical data than their analytic workflows were built to interpret, and the bottleneck has shifted from data generation to decision support in R&D [Business Wire, October 2026].
Omabit is aiming at the intersection of life-science informatics, translational analytics, and AI-assisted knowledge synthesis, but the available public record does not support a company-specific TAM, SAM, or SOM estimate. The company describes a platform that combines internal genomic, clinical, and scientific data with published research to guide R&D decisions, with an initial focus on clinical-development, biomarker, and translational teams [Business Wire, October 2026]. That positioning is directionally consistent with a broader genomics and drug-development software spend envelope, yet the evidence here is still category-level rather than market-sizing specific to Omabit’s wedge [GenomeWeb, October 2026].
Demand appears to be driven less by new data creation than by the difficulty of turning existing data into usable hypotheses. In Omabit’s own description, users are expected to compare treatment-response differences, interpret findings against published studies and comparison datasets, and use the result to plan trials or support regulatory discussions [Business Wire, October 2026]. If that workflow resonates, the budget line could sit adjacent to bioinformatics software, translational medicine tooling, and clinical-development analytics, with substitution pressure coming from internal computational-biology teams, CRO-led analysis, and general-purpose data-science stacks rather than only from direct startup peers [Business Wire, October 2026] [GenomeWeb, October 2026].
The adjacent market structure matters because Omabit does not appear to be selling primary data generation, lab automation, or a single-purpose diagnostic. GenomeWeb characterized the company as a genomics data analysis AI startup, while the company’s own announcement framed the product as scientific decision-making support in drug development [GenomeWeb, October 2026] [Business Wire, October 2026]. That suggests a software layer that could compete for budget across several existing workflows, including biomarker analysis, translational research interpretation, and trial-planning support, which can be attractive if the product shortens analysis cycles without forcing a full platform replacement.
Regulatory and macro forces are supportive in principle, though the public evidence is still thin on how much this converts into near-term procurement. Omabit says the platform can be used to support regulatory discussions, which points to a market need for reproducible, documented interpretation rather than only exploratory analysis [Business Wire, October 2026]. The stronger macro signal is simply capital formation and ecosystem interest: the company joined the StartX Summer 2026 cohort in June 2026 and later raised a $2 million seed round led by Bright Ventures in October 2026, indicating that investors see room for AI-native tooling in life-science R&D even at a very early stage [Omabit, June 2026] [Business Wire, October 2026].
| Market lens | Public evidence | Implication for Omabit |
|---|---|---|
| Core workflow | Analysis of genomic, clinical, and scientific data for R&D decisions [Business Wire, October 2026] | Points to informatics and decision-support budgets rather than wet-lab instrumentation |
| Initial buyer teams | Clinical-development, biomarker, and translational teams [Business Wire, October 2026] | Suggests departmental adoption path before broader enterprise standardization |
| Substitute solutions | Internal computational analysis, published-research review, and existing data-science workflows (inference based on described workflow) [Business Wire, October 2026] | Competitive pressure may come from labor and incumbent process, not only software vendors |
| Macro validation | StartX cohort acceptance and seed financing [Omabit, June 2026] [Business Wire, October 2026] | Early ecosystem support is visible, but commercial demand remains unquantified |
The table points to a market that is real but still better described by workflow pain than by clean public sizing. For investors, that usually means the early diligence burden shifts to budget ownership, replacement behavior, and proof that teams will trust AI-mediated interpretation in regulated R&D settings.
One source, partially checked -- This section relies mainly on Business Wire and GenomeWeb, with partial corroboration from Omabit's StartX announcement. No independent third-party market-sizing report was available in the provided sources.
The Competitive Field
Competitive map
MIXED Omabit is positioning itself less as a raw-data infrastructure vendor and more as an interpretation layer for life-science R&D teams that need genomic and clinical evidence translated into decisions, which places it between established bioinformatics software, AI-native analysis startups, and internal workflows still run through code-heavy tools and scientific services [Business Wire, October 2026] [GenomeWeb, October 2026] [Omabit, Unknown].
The first competitive bucket is the incumbent stack already embedded inside pharma and biotech research. Public sources here do not name Omabit-specific rivals, so the cleaner read is by function rather than logo. On one side sit established bioinformatics and data-analysis environments that research teams already use for omics interpretation, literature review, and trial-related analysis; on the other sit internal computational-biology teams and contract research workflows that can still absorb this work manually or semi-manually. Omabit's own product description emphasizes natural-language analysis, predictive modeling, and no-code report generation for clinical-development, biomarker, and translational teams, which suggests the company is trying to compress work that otherwise spans analysts, biologists, and software tooling rather than replace a single incumbent product outright [Business Wire, October 2026] [Omabit, Unknown].
A second bucket is the newer AI-native challenger set, even if the available sources stop short of naming direct peers. GenomeWeb characterizes Omabit as a genomics-data-analysis AI startup, and the company says it combines internal genomic and clinical data with published research to support R&D decisions [GenomeWeb, October 2026] [Business Wire, October 2026]. That positioning matters because the nearest substitutes may not be classic life-science software vendors at all, but horizontal AI copilots, in-house LLM workflows, and consulting-style analysis wrapped in software. In that frame, Omabit competes on scientific usability and domain specificity, not just model quality.
Where Omabit appears strongest today is team-market fit and product focus, though the edge is still early and somewhat perishable. The founding bench combines computational biology, machine learning, and translational-science backgrounds, according to the company team page and founder LinkedIn profiles, and scientific adviser Michael Snyder adds some external credibility to the scientific posture [Omabit, Unknown] [LinkedIn, retrieved 2026] [Business Wire, October 2026]. StartX admission provides a modest network advantage for early customer and talent access, and the company has at least framed a specific workflow wedge around post-experiment interpretation and trial-planning support rather than broad laboratory automation [Omabit, June 2026] [Business Wire, October 2026]. That said, durability is not yet evident from public evidence. There are no disclosed customers, deployments, or proprietary-data partnerships in the materials reviewed, so any lead based on talent and workflow design can narrow quickly if better-capitalized vendors add similar interfaces or if buyers prefer to keep sensitive analysis inside existing platforms [Business Wire, October 2026] [GenomeWeb, October 2026].
The exposure is straightforward. Omabit does not yet appear to own a privileged distribution channel, a regulatory moat, or a disclosed exclusive dataset, and those are usually the assets that make a life-sciences software position harder to dislodge. The company also raised a relatively small $2 million seed round led by Bright Ventures, enough to fund product development but not enough on its own to dominate enterprise sales cycles in pharma if larger software vendors or better-funded AI biology companies target the same budget line [Business Wire, October 2026] [Datapile, October 2026]. The practical risk is that buyers may view Omabit as an evaluation tool or specialist assistant rather than a system of record, which would leave it vulnerable to bundling by broader platforms or to internal teams recreating parts of the workflow with general-purpose models.
The most plausible 18-month scenario is a sorting process between domain-specific tools that can show repeatable scientific output and those that remain promising demos. If Omabit can turn its current positioning into named deployments with translational or biomarker teams, the likely winner is Omabit itself, because the product story is already narrow enough to map to a real buyer and real workflow [Business Wire, October 2026]. If, instead, the category shifts toward horizontal AI embedded into software that customers already use, the likely loser is the standalone interpretation layer without entrenched distribution, and Omabit would fit that risk profile based on public evidence today [GenomeWeb, October 2026] [Business Wire, October 2026].
No independent source found -- This section rests mainly on company descriptions and limited third-party coverage; no named direct competitors, customer wins, or independent comparative benchmarks were confirmed in the public sources reviewed.
Opportunity
PUBLIC
The prize here is large if Omabit can become the analysis layer that life-science R&D teams trust after experiments are run but before clinical and portfolio decisions are made, because that sits close to budget, timeline, and regulatory risk inside drug development [Business Wire, October 2026] [GenomeWeb, October 2026].
The headline opportunity is straightforward. Omabit is not presenting itself as a lab automation company or a point bioinformatics tool, but as a decision-support platform that combines a company’s internal genomic, clinical, and scientific data with published research to guide R&D choices [Business Wire, October 2026]. That positioning matters because budgets for translational analysis, biomarker work, and clinical interpretation can persist across multiple programs when a tool becomes part of how teams explain response differences, compare findings with prior studies, and frame future trials or regulatory discussions [Business Wire, October 2026]. The setup is still early, and most product claims remain company-described, but the presence of a named seed round, a specialist use case in genomics data analysis, and participation in StartX gives the company a plausible path into a category where credibility and workflow fit matter more than broad consumer-style distribution [GenomeWeb, October 2026] [Business Wire, October 2026] [Omabit, June 2026].
The range of upside depends on which wedge converts first. The table below frames three public-evidence scenarios rather than a single deterministic path.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Translational command center | Omabit becomes a standard analysis environment for clinical-development, biomarker, and translational teams, first in smaller biotech and then in larger pharma-adjacent groups | A repeatable workflow for comparing treatment-response differences and producing decision-ready outputs for trial planning or regulatory discussions [Business Wire, October 2026] | Those are the exact initial user groups and jobs the company has publicly identified, which suggests an intentionally narrow wedge rather than a broad platform claim [Business Wire, October 2026] |
| No-code genomics interpretation layer | The platform wins adoption as a natural-language interface for variant, biomarker, differential-expression, and pathway analysis, reducing dependence on specialist coding talent | A product release or reference account that proves non-computational scientists can generate reports and figures directly [Omabit] | Omabit’s public materials describe natural-language analysis and report generation without code, which fits a persistent pain point in life-science teams that sit between biology and computation [Business Wire, October 2026] [Omabit] |
| Multi-modal R&D system of record | Omabit extends from analysis into the place where internal datasets and external literature are interpreted together across programs, making it hard to displace once embedded in scientific review cycles | Integrations into life-science R&D workflows funded by the seed round [Business Wire, October 2026] | The company said seed proceeds will support platform development and workflow integrations, and GenomeWeb independently characterized the company as a genomics-data-analysis startup rather than a single-purpose application [Business Wire, October 2026] [GenomeWeb, October 2026] |
What compounding could look like is less about a classic consumer network effect and more about workflow entrenchment. If Omabit helps one team interpret treatment-response differences, compare them against published studies, and turn the result into trial-planning or regulatory-support material, the next logical step is adjacent scientific work on biomarkers, pathways, or cohort segmentation using the same internal datasets [Business Wire, October 2026]. In that model, every successful project deepens the company’s fit with a customer’s data structure, reporting conventions, and decision process.
There is also an early credibility flywheel visible in the public record, even if it is still thin. The company has assembled three co-founders with computational biology, machine learning, and life-science backgrounds on its own account, added scientific adviser Michael Snyder, joined StartX in mid-2026, and then announced a Bright Ventures-led seed round in October 2026 [Business Wire, October 2026] [Omabit, June 2026] [Omabit]. None of that proves commercial traction, but it does suggest a familiar pattern in technical software for science: advisory depth and founder-market fit can help win initial pilots, those pilots can justify workflow integrations, and integrations can improve retention if the product becomes part of recurring scientific review.
The size of the win is best framed conditionally because no public market-sizing figure or direct public comparable is provided in the source set. If the strongest scenario plays out and Omabit becomes a durable software layer for translational and clinical-interpretation workflows across biotech and pharma R&D teams, this could support venture-scale outcomes well beyond the current $2 million seed footing (scenario, not a forecast) [Business Wire, October 2026]. The key reason the upside is real rather than purely aspirational is that the company is aiming at a high-value decision point in drug development, where better interpretation of genomic and clinical data can affect trial design, biomarker strategy, and regulatory preparation, and where even modest workflow adoption can expand across programs once embedded [Business Wire, October 2026] [GenomeWeb, October 2026].
No independent source found -- This section relies primarily on company statements in Business Wire and Omabit materials, with partial independent corroboration of the seed round and category framing from GenomeWeb.
Sources
Publicly reported
[Business Wire, October 2026] Omabit Announces Seed Financing to Advance Scientific Decision-Making in Drug Development | https://www.businesswire.com/news/home/20261027064838/en/
[GenomeWeb, October 2026] Genomics Data Analysis AI Startup Omabit Raises $2M Seed Money | https://www.genomeweb.com/technology/ai/gnw-omabit-ai-data-analysis-seed-financing-2m-20261026/
[Omabit, June 2026] Omabit Joins StartX Summer 2026 Cohort | https://omabit.com/news/
[Omabit] Team · Omabit | https://omabit.com/team/
[LinkedIn, retrieved 2026] Elena Cassidy - CEO and Co-Founder at Omabit | https://www.linkedin.com/in/elena-cassidy-096ba5234
[Datapile, October 2026] Omabit raises $2.0M Seed (United States, October 2026) | https://datapile.co/funding-news/omabit-19659
Articles about Omabit
- A Stanford-Backed AI Startup Is Translating Lab Data for Drug Developers — The San Francisco startup, founded by a molecular biologist, an ex-Meta AI engineer, and a serial biotech entrepreneur, is targeting the translational research bottleneck.